It kills bacteria by inhibiting bacterial cell wall synthesis and has high resistance to β-lactamase produced by bacteria. Some common Gram-positive, Gram-negative aerobic and anaerobic pathogens are highly sensitive to this product. It is resistant to Pseudomonas aeruginosa, most strains of enterococci, and Escherichia coli.

1) It has strong antibacterial activity against Gram-positive bacteria and also has broad-spectrum antibacterial activity against bacteria including Gram-negative bacteria. At the same time, it has strong antibacterial activity against non-fermenting Gram-negative bacteria such as Pseudomonas aeruginosa. The drug has a bactericidal effect and is stable to β-lactamase produced by various bacteria. 2) It has excellent therapeutic effects when used for experimental infections (mice). 3) It is sensitive to bacteria resistant to penicillins, other cephalosporins or aminoglycoside antibiotics, especially Pseudomonas aeruginosa. 4) Mechanism of action: It has a strong affinity with 1A, 1B and 3 of penicillin-binding protein (PBP), inhibits the synthesis of bacterial cell walls, and thus exerts a bactericidal effect.

1) It has strong antibacterial activity against Gram-positive bacteria and also has broad-spectrum antibacterial activity against bacteria including Gram-negative bacteria. At the same time, it has strong antibacterial activity against non-fermenting Gram-negative bacteria such as Pseudomonas aeruginosa. The drug has a bactericidal effect and is stable to β-lactamase produced by various bacteria. 2) It has excellent therapeutic effects when used for experimental infections (mice). 3) It is sensitive to bacteria resistant to penicillins, other cephalosporins or aminoglycoside antibiotics, especially Pseudomonas aeruginosa. 4) Mechanism of action: It has a strong affinity with 1A, 1B and 3 of penicillin-binding protein (PBP), inhibits the synthesis of bacterial cell walls, and thus exerts a bactericidal effect.

This product is a second-generation cephalosporin for intravenous or intramuscular injection. It has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against influenza bacilli and gonococci (including beta-lactamase-producing strains). Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci, and its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by a concentration of 4.0-8.3 mg/L of this product. Most streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes and group B streptococci) are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product, while fecal streptococci, methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis strains are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, group B streptococci and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, and is sensitive to type IV beta-lactamase.

This product is a second-generation cephalosporin for intravenous or intramuscular injection. This product has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.